Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
Incyte presented new Phase 1 data at ESMO 2026 for its KRAS G12D inhibitor INCB161734 and TGFβR2×PD-1 bispecific INCA33890 across pancreatic and colorectal cancers. INCB161734 plus mFOLFIRINOX in first-line metastatic PDAC showed an 89% ORR and 100% disease control rate with a 90% six-month PFS landmark; the Phase 3 DAWN-303 is ongoing with topline data expected in 2028. In heavily pretreated KRAS G12D-mutated CRC, INCB161734 plus cetuximab achieved a 36% ORR, supporting a planned Phase 3 DAWN-302 initiation in H1 2027. INCA33890 in first-line MSS CRC with FOLFOX and bevacizumab achieved a 71% ORR and 100% DCR, reinforcing the ongoing Phase 3 NEXERA-303 with topline data expected in 2029.
Key figures
- Drug Name
- INCB161734 (KRAS G12D inhibitor); INCA33890 (TGFβR2×PD-1 bispecific antibody)
- Phase Of Trial
- Phase 1 data supporting ongoing Phase 3 (DAWN-303, NEXERA-303); Phase 3 DAWN-302 planned H1 2027
- Mss crc 1l dcr
- 100%
- Mss crc 1l orr
- 71%
- Pdc dcr gemnabp
- 96%
- Pdc orr gemnabp
- 69% (confirmed) / 58% (confirmed + pending)
- Dawn 303 topline
- 2028
- Mss crc 1l 6mo pfs
- 81%
- Nexera 303 topline
- 2029
- Pdc dcr mfolfirinox
- 100%
- Pdc orr mfolfirinox
- 89% (confirmed) / 81% (confirmed + pending)
- Crc combo orr cetuximab
- 36%
- Pdc 6mo pfs mfolfirinox
- 90%
- Crc combo median pfs months
- 7.2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.